Esmark Inc. Announces All-Cash Public Offer for U.S. Steel Shares
14.8.2023 21:54:00 EEST | Business Wire | Press release
Esmark, Inc. announced today a voluntary public cash and exchange offer for all issued and outstanding shares in U.S. Steel Corporation (NYSE: X) (“U.S. Steel”) for $35 USD per share. The initial offer period runs from August 14, 2023, to November 30, 2023, and may be extended. Completion of the Offer is expected in Q4 2023, subject to regulatory and antitrust clearances.
“With more than 40 years of steel industry experience, and as a former executive and statutory representative of U.S. Steel, I have significant intimacy with the steel business in the U.S. and around the globe,” said James P. Bouchard, Chairman & CEO of Esmark, Inc., Executive Committee Member of the American Steel Institute and the European Steel Association (Eurofer). Bouchard is Forever Chairman & CEO of Esmark/Wheeling Pittsburg Steel (Ticker Symbol: ESMK). Under Bouchard’s helm, Esmark/Wheeling Pittsburg was the fourth largest steel company in the U.S.
Bouchard continued, “This is an exciting time as the entire American Steel industry is restructuring, and with Esmark’s long-standing history of excellence, we are anxious to continue to grow and we’re well positioned to come in and operate.”
Founded in 1901, United States Steel Corporation is a steel producer serving the automotive, construction, appliance, energy, containers, and packaging industries.
Prior to founding Esmark, Bouchard was Vice President-Commercial for U.S. Steel in Europe, residing in Kosice, Slovak Republic. He was a member of the executive team that U.S. Steel dispatched to Kosice after having acquired the Slovakian National Steel Company (VSZ).
Bouchard was widely credited with the successful commercial restructuring, implementation, and subsequent growth strategy of the company's European sales, marketing, strategic planning, and customer service initiatives, and was ultimately responsible for the company's commercial operations in 42 countries. The Kosice operation became the most profitable steel asset owned by U.S. Steel at that time.
Esmark Steel Group, a wholly owned subsidiary of Esmark, Inc., is one of the United States’ leading processors and distributors of value-added flat-rolled steel and the third-largest U.S. producer of tin plate steel. We offer the products, services and innovations to help our customers gain and sustain the competitive edge in their industries.
More About Mr. Bouchard:
Bouchard is the Founder, Chairman, and Chief Executive Officer of Esmark Inc. and its predecessor and controlling shareholder, the Bouchard Group, which was formed in 1995 with an initial $500 investment and is still 100 percent privately owned by Bouchard. Over the years, the Bouchard Group has grown and evolved into a diversified VC Investment Holding Company with strategic assets engaged in the Industrial, Energy, Technology, Real Estate, Commodities industries, and Youth Sports and Development.
Esmark and the Bouchard Group's roots are firmly planted in the steel industry. In 2003, the company acquired two Chicago area steel services companies, Electric Coating Technologies and Sun Steel. The acquisitions served as the genesis for Bouchard to found and bring the legendary Fortune 50 Esmark name and brand back to life when he formed the new Esmark Inc. II in 2003 to focus on steel company acquisitions. Bouchard subsequently transferred his Bouchard Group steel assets and capitalized the new Esmark II in 2004.
In 2007, he and his management team successfully completed the first hostile tender/reverse merger in the history of the United States with the merger of Wheeling Pittsburgh Steel Corporation (formerly NASDAQ: WPSC) and Esmark II. Bouchard served as Chairman and Chief Executive Officer of the iconic Wheeling-Pittsburgh Steel Corporation in 2006 before completing the merger with Esmark in 2007. He then built Esmark II into a publicly traded (formerly NASDAQ: ESMK), $3 billion company before it was ultimately sold to OAO Severstal for $1.3 billion in August 2008.
Bouchard, through the Bouchard Group, later repurchased the Esmark name, trademark, and intellectual property from OAO Severstal and brought the Esmark name and respective brand back to life for a third time when he founded Esmark Inc. III in October of 2008 with no revenue and one employee. The Bouchard Group is Esmark's III controlling shareholder. Esmark III is one of the nation's fastest growing companies with assets in excess of $200 million. With its diverse portfolio of companies, Esmark III generates more than $500 million in revenue annually.
During his 30-year career, Bouchard has served on the Board of Directors of a number steel industry organizations and companies, including the American Iron and Steel Institute (AISI) in Washington, D.C. He also formerly served on the C.D.E. committee for Eurofer in Brussels, Belgium, and the Board of Directors for Wheeling-Nisshan Steel Corporation and Ohio Coatings Company.
In addition to serving as Chairman of the Board and CEO of Esmark Inc., Esmark Steel Group, Inc., and the Bouchard Group, he is Co-Chairman of Ohio Coatings Company (OCC) in Yorkville, Ohio. Bouchard also currently serves as a member of the Board of Trustees at Loyola University-Chicago and Robert Morris University. Bouchard is a Dartmouth University Tuck School of Business Entrepreneurial Management Instructor. As well, he is on the Board of Directors for several Pittsburgh-based organizations including FC Pittsburgh Soccer Club, the Imani Christian Academy, the Quaker Valley Hockey Association, and the City of Champions for Haiti humanitarian group.
Bouchard is also the Chairman and majority owner of Johnstown Sports Partners LLC and majority owner of the NAHL's Johnstown Tomahawks Hockey Team in Johnstown, PA.
Bouchard is the recipient of numerous industry and philanthropic awards for his accomplishments and contributions. In 2005, he was nominated and named as an Illinois Finalist of the prestigious Ernst & Young Entrepreneur of the Year Award. In March 2006, the Association of Steel Distributors bestowed their highest honor on him as "Steel Man of the Year." In 2007, he was inducted into the Hinsdale Central High School Hall of Fame, the youngest inductee in the history of the school. He is a recipient of the Hinsdale Central, James Carmanani Award. Bouchard was also honored by Loyola University as the 2007-08 recipient of the Chicago Damen Award for distinguished alumni. And in 2010, he was named a Paul Harris Fellow by Rotary International for his humanitarian relief efforts during the aftermath of the earthquake in Haiti. In 2012, Bouchard was named Sewickley, Pennsylvania's "Man of the Year" for his ongoing support of multiple children's charities, youth sports and development programs, and other humanitarian organizations throughout Western Pennsylvania and Pittsburgh's inner city. Also in 2012, Bouchard was named a finalist for "CEO of the Year" by global publishing concern Platts International and subsidiary Steel Business Briefing for his years of leadership, vision, and innovation in the steel industry. He is a part of the Pittsburgh City of Champions Hall of Fame and the Quaker Valley Hall of Fame.
James P. Bouchard family, along with the Esmark family of companies, continue to be tireless supporters of a wide range of educational, family health and wellness, youth sports and recreation programs in Pennsylvania, Illinois, and in Haiti including the Helen E. Bouchard Scholarship Award (totaling $500,000 to 75 recipients), with donations totaling more than $10 million since 2003.
About Esmark, Inc.
Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814019728/en/
Contact information
Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com
(708) 898-5550
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
